Dr Suppes receives funding from the following sources: Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceutica, National Institutes of Mental Health, Novartis, Robert Wood Johnson Pharmaceutical Research Institute, and The Stanley Medical Research Institute. Dr Suppes also serves on advisory boards and has consulting agreements with Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly Research Laboratories, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceutica, Johnson & Johnson Pharmaceutical Research & Development, Pfizer, Pharmaceutical Research Institute (PRI), Ortho McNeil Pharmaceutical, UCB Pharma, and Novartis Pharmaceuticals. Drs Ozcan and Carmody have no commercial associations that pose a conflict of interest with this manuscript.
Response to clozapine of rapid cycling versus non-cycling patients with a history of mania
Version of Record online: 28 JUN 2004
Volume 6, Issue 4, pages 329–332, August 2004
How to Cite
Suppes, T., Erkan Ozcan, M. and Carmody, T. (2004), Response to clozapine of rapid cycling versus non-cycling patients with a history of mania. Bipolar Disorders, 6: 329–332. doi: 10.1111/j.1399-5618.2004.00119.x
- Issue online: 28 JUN 2004
- Version of Record online: 28 JUN 2004
- Received 28 July 2003, revised and accepted for publication 26 February 2004
- bipolar disorder;
- rapid cycling;
Objective: Rapid cycling (RC) bipolar disorder (BD) patients often do not respond fully to mood-stabilizers. Atypical antipsychotics including clozapine may be good candidates as an alternative mood-stabilizer for these patients.
Methods: Twenty-eight treatment-resistant patients with either Bipolar Disorder Type I (n = 20), or Schizoaffective Disorder Bipolar Type (n = 8) received clozapine add-on therapy. Patients were followed for up to 1 year. Patients were seen monthly and assessed on a number of symptom domains.
Results: Fifteen of 28 patients met RC criteria. Differences between groups was non-significant for reported age of onset, age at study entry, past history of treatment or hospitalization, or diagnosis. However, significantly more women were RC. More than 80% of patients in either group showed at least some improvement over the 1-year study. Random regression analyses found the non-rapid cycling (NRC) group experienced significantly greater improvement than RC patients (p < 0.0001).
Conclusions: Clozapine is more effective in NRC patients with a history of mania in comparison to patients with a recent history of RC.